{"filing":{"accession_number":"0001628280-26-055484","cik":"0001680367","ticker":"STTK","company_name":"Shattuck Labs, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"sttk-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk-20260811.htm"},"events":[{"id":26823,"run_id":24397,"accession_number":"0001628280-26-055484","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 11, 2026. The filing discloses quarterly financial results including R\u0026D expenses ($11.7M), G\u0026A expenses ($4.5M), net loss ($15.2M or $0.12 per share), and cash position ($208.3M), along with clinical development milestones and business highlights. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02, which is the standard Item for earnings disclosures.","company_name":"Shattuck Labs, Inc.","ticker":"STTK","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28092,"accession_number":"0001628280-26-055484","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 11, 2026. The filing discloses quarterly financial results including R\u0026D expenses ($11.7M), G\u0026A expenses ($4.5M), net loss ($15.2M or $0.12 per share), and cash position ($208.3M), along with clinical development milestones and business highlights. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02, which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T10:59:42.378052+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28092,"accession_number":"0001628280-26-055484","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 11, 2026. The filing discloses quarterly financial results including R\u0026D expenses ($11.7M), G\u0026A expenses ($4.5M), net loss ($15.2M or $0.12 per share), and cash position ($208.3M), along with clinical development milestones and business highlights. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02, which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T10:59:42.378052+00:00","company_name":"Shattuck Labs, Inc.","ticker":"STTK","filing_date":"2026-08-11"}]}